Corvus Pharmaceuticals Announces Publication of Biochemistry and Preclinical Data Demonstrating Potential of ITK Inhibition with Soquelitinib as a Novel Approach to Modulate Tumor Immunity
Corvus Pharmaceuticals (NASDAQ: CRVS) announced the publication of preclinical data for soquelitinib, their lead ITK inhibitor program, in npj Drug Discovery. The research demonstrates soquelitinib's potential as a novel approach to modulate tumor immunity through its mechanism of action - suppressing Th2 and Th17 cytokine production while sparing Th1 cytokines.
The data shows that soquelitinib increases effector function of cytotoxic CD8 positive T cells and enhances memory T cell function. The company is currently conducting a Phase 3 clinical trial for relapsed peripheral T cell lymphoma (PTCL) and a Phase 1 trial for atopic dermatitis, with plans to initiate another Phase 1 trial in solid tumors.
Corvus Pharmaceuticals (NASDAQ: CRVS) ha annunciato la pubblicazione di dati preclinici per soquelitinib, il loro principale programma inibitore di ITK, su npj Drug Discovery. La ricerca dimostra il potenziale di soquelitinib come un approccio innovativo per modulare l'immunità tumorale attraverso il suo meccanismo d'azione: sopprimere la produzione di citochine Th2 e Th17, risparmiando le citochine Th1.
I dati mostrano che soquelitinib aumenta la funzione effettrice delle cellule T citotossiche CD8 positive e migliora la funzione delle cellule T di memoria. Attualmente, l'azienda sta conducendo un studio clinico di Fase 3 per il linfoma periferico a cellule T recidivante (PTCL) e un studio di Fase 1 per la dermatite atopica, con piani per avviare un altro studio di Fase 1 in tumori solidi.
Corvus Pharmaceuticals (NASDAQ: CRVS) anunció la publicación de datos preclínicos para soquelitinib, su principal programa de inhibidores de ITK, en npj Drug Discovery. La investigación demuestra el potencial de soquelitinib como un enfoque novedoso para modular la inmunidad tumoral a través de su mecanismo de acción: suprimir la producción de citoquinas Th2 y Th17, mientras se preservan las citoquinas Th1.
Los datos muestran que soquelitinib aumenta la función efectora de las células T citotóxicas positivas para CD8 y mejora la función de las células T de memoria. La compañía está llevando a cabo actualmente un ensayo clínico de Fase 3 para el linfoma periférico de células T (PTCL) recidivante y un ensayo de Fase 1 para la dermatitis atópica, con planes de iniciar otro ensayo de Fase 1 en tumores sólidos.
코르버스 제약 (NASDAQ: CRVS)는 npj Drug Discovery에서 소퀠리티닙의 전임상 데이터 발표를 발표했습니다. 이 연구는 소퀠리티닙이 Th2 및 Th17 사이토카인의 생산을 억제하면서 Th1 사이토카인을 보호하는 작용 메커니즘을 통해 종양 면역을 조절하는 새로운 접근법으로서의 잠재력을 보여줍니다.
데이터는 소퀠리티닙이 CD8 양성 세포독성 T세포의 효과 기능을 증가시키고 기억 T세포 기능을 향상한다는 것을 보여줍니다. 현재 회사는 재발성 말초 T세포 림프종(PTCL)에 대한 3상 임상 시험과 아토피 피부염에 대한 1상 시험을 진행 중이며, 고형 종양에 대한 또 다른 1상 시험을 시작할 계획입니다.
Corvus Pharmaceuticals (NASDAQ: CRVS) a annoncé la publication de données précliniques concernant soquelitinib, leur principal programme d'inhibiteurs ITK, dans npj Drug Discovery. La recherche démontre le potentiel de soquelitinib comme une nouvelle approche pour moduler l'immunité tumorale par son mécanisme d'action – en supprimant la production de cytokines Th2 et Th17 tout en épargnant les cytokines Th1.
Les données montrent que soquelitinib augmente la fonction effectrice des cellules T cytotoxiques CD8 positives et améliore la fonction des cellules T mémoires. L'entreprise mène actuellement un essai clinique de phase 3 pour le lymphome périphérique à cellules T récurrent (PTCL) et un essai de phase 1 pour la dermatite atopique, avec des plans pour initier un autre essai de phase 1 sur les tumeurs solides.
Corvus Pharmaceuticals (NASDAQ: CRVS) gab die Veröffentlichung von präklinischen Daten zu soquelitinib, ihrem führenden ITK-Hemmerprogramm, in npj Drug Discovery bekannt. Die Forschung zeigt das Potenzial von soquelitinib als neuartige Methode zur Modulation der Tumorimmunität durch seinen Wirkmechanismus – die Unterdrückung der Th2- und Th17-Zytokinproduktion bei Erhaltung der Th1-Zytokine.
Die Daten zeigen, dass soquelitinib die Effektoraktivität zytotoxischer CD8-positiver T-Zellen erhöht und die Gedächtnis-T-Zellfunktion verbessert. Das Unternehmen führt derzeit eine Phase-3-Studie bei rezidivierenden peripheren T-Zell-Lymphomen (PTCL) und eine Phase-1-Studie bei atopischer Dermatitis durch, mit Plänen, eine weitere Phase-1-Studie bei soliden Tumoren zu starten.
- Publication in prestigious peer-reviewed Nature portfolio journal validates scientific approach
- Advancement to Phase 3 clinical trials for PTCL indicates late-stage development progress
- Multiple ongoing clinical trials across different indications show pipeline expansion
- None.
Insights
The publication of preclinical data for soquelitinib in a prestigious Nature portfolio journal demonstrates promising scientific validation of Corvus's ITK inhibitor technology. The data reveals several key mechanistic advantages:
- Selective modulation of immune responses through suppression of Th2 and Th17 cytokines while preserving Th1 cytokines
- Enhancement of CD8+ T cell effector function and memory T cell development
- Potential for both monotherapy and combination approaches with checkpoint inhibitors
Currently advancing in Phase 3 trials for PTCL and Phase 1 for atopic dermatitis, with planned expansion into solid tumors, soquelitinib shows broad therapeutic potential across both oncology and immunology. The multi-institutional collaboration behind this research adds credibility to the findings.
This peer-reviewed publication represents a significant milestone for Corvus Pharmaceuticals, validating their lead drug candidate's mechanism of action. With a market cap of
- PTCL market potential:
$1.5B by 2027 - Atopic dermatitis market: projected to reach
$24B by 2027 - Solid tumor applications could further expand the addressable market
The publication in a prestigious journal may attract potential partnerships or licensing deals, particularly given the broad applicability of the technology platform.
Data published in peer-reviewed npj Drug Discovery, a Nature portfolio journal
BURLINGAME, Calif., Dec. 04, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced the publication of preclinical data highlighting the potential of soquelitinib, the Company’s lead ITK inhibitor program, as a novel approach to modulate tumor immunity. The data was published in npj Drug Discovery (part of the Nature portfolio of journals), an open access, international, peer-reviewed journal dedicated to publishing the highest quality research relevant to all aspects of drug design and discovery.
The publication, entitled “Synthesis and characterization of soquelitinib a selective ITK inhibitor that modulates tumor immunity,” includes a detailed overview of soquelitinib’s mechanism of action – suppressing Th2 and Th17 cytokine production and sparing Th1 cytokines – that serves as a novel approach to cancer immunotherapy, both as a single agent and in combination with immune checkpoint inhibitors. The data also shows that soquelitinib increases effector function of cytotoxic CD8 positive T cells and leads to an increase in memory T cells with enhanced effector function.
“We continue to build awareness of the unique potential of soquelitinib and ITK inhibition as a novel therapy that modulates parallel signaling pathways in the immune system for the treatment of oncology and immune diseases,” said Richard A. Miller, M.D., co-founder, president and chief executive officer of Corvus. “This publication in npj Drug Discovery highlights foundational work characterizing key properties and mechanisms of soquelitinib conducted at Corvus and with academic collaborators, and we are excited to now be in clinical development for PTCL and atopic dermatitis, along with a broad range of additional opportunities for soquelitinib and our next-generation ITK inhibitors.”
The published research was a result of collaborations between scientists at Corvus and researchers at the University of Michigan, The Ohio State University, Peking University, Stanford University and Angel Pharmaceuticals Co., Ltd. The publication is available online at the Nature website and on the Publications and Presentations page of the Corvus website.
Corvus is currently developing soquelitinib and its next-generation ITK inhibitors for oncology and immune diseases. The Company is enrolling patients in a registrational Phase 3 clinical trial in patients with relapsed peripheral T cell lymphoma (PTCL) and a randomized, placebo-controlled Phase 1 clinical trial in patients with moderate to severe atopic dermatitis. The Company plans to initiate a Phase 1 clinical trial of soquelitinib in patients with solid tumors.
About Corvus Pharmaceuticals
Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company pioneering the development of ITK inhibition as a new approach to immunotherapy for a broad range of cancer and immune diseases. The Company’s lead product candidate is soquelitinib, an investigational, oral, small molecule drug that selectively inhibits ITK. Its other clinical-stage candidates are being developed for a variety of cancer indications. For more information, visit www.corvuspharma.com.
About Soquelitinib
Soquelitinib (formerly CPI-818) is an investigational small molecule drug given orally designed to selectively inhibit ITK (interleukin-2-inducible T cell kinase), an enzyme that is expressed predominantly in T cells and plays a role in T cell and natural killer (NK) cell immune function. Soquelitinib has been shown to affect T cell differentiation and induce the generation of Th1 helper cells while blocking the development of both Th2 and Th17 cells and production of their secreted cytokines. Th1 T cells are required for immunity to tumors, viral infections and other infectious diseases. Th2 and Th17 helper T cells are involved in the pathogenesis of many autoimmune and allergic diseases. The Company believes the inhibition of specific molecular targets in T cells may be of therapeutic benefit for patients with cancers, including solid tumors, and in patients with autoimmune and allergic diseases. Recent studies have demonstrated that ITK controls a switch between the differentiation of Th17 proinflammatory cells and T regulatory suppressor cells. Inhibition of ITK leads to a shift toward T regulatory cell differentiation which has the potential to suppress autoimmune and inflammatory reactions. Based on interim results from a Phase 1/1b clinical trial in patients with refractory T cell lymphomas, which demonstrated tumor responses in very advanced, refractory, difficult to treat T cell malignancies, the Company has initiated a registrational Phase 3 clinical trial (NCT06561048) of soquelitinib in patients with relapsed PTCL. Soquelitinib is also now being investigated in a randomized placebo-controlled phase 1 clinical trial in patients with atopic dermatitis.
Forward-Looking Statements
This press release contains forward-looking statements, including statements related to the potential efficacy of the Company’s product candidates including soquelitinib; the potential use of soquelitinib to treat PTCL, solid tumors and a broad range of autoimmune diseases; and the conduct, enrollment in and timing of clinical trials, including the Company’s Phase 3 clinical trial for PTCL with soquelitinib and Phase 1 clinical trials in patients with moderate to severe atopic dermatitis and in patients with solid tumors. All statements other than statements of historical fact contained in this press release are forward-looking statements. These statements often include words such as “believe,” “expect,” “anticipate,” “intend,” “plan,” “estimate,” “seek,” “will,” “may” or similar expressions. Forward-looking statements are subject to a number of risks and uncertainties, many of which involve factors or circumstances that are beyond the Company’s control. The Company’s actual results could differ materially from those stated or implied in forward-looking statements due to a number of factors, including but not limited to risks detailed in the Company’s Quarterly Report on Form 10-Q for the three months ended September 30, 2024, filed with the Securities and Exchange Commission on November 12, 2024, as well as other documents that may be filed by the Company from time to time with the Securities and Exchange Commission. In particular, the following factors, among others, could cause results to differ materially from those expressed or implied by such forward-looking statements: the Company’s ability to demonstrate sufficient evidence of efficacy and safety in its clinical trials of its product candidates; the accuracy of the Company’s estimates relating to its ability to initiate and/or complete preclinical studies and clinical trials and release data from such studies and clinical trials; the results of preclinical studies and interim data from clinical trials not being predictive of future results; the Company’s ability to enroll sufficient numbers of patients in its clinical trials; the unpredictability of the regulatory process; regulatory developments in the United States and other foreign countries; the costs of clinical trials may exceed expectations; and the Company’s ability to raise additional capital. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, it cannot guarantee that the events and circumstances reflected in the forward-looking statements will be achieved or occur, and the timing of events and circumstances and actual results could differ materially from those projected in the forward-looking statements. Accordingly, you should not place undue reliance on these forward-looking statements. All such statements speak only as of the date made, and the Company undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise.
INVESTOR CONTACT:
Leiv Lea
Chief Financial Officer
Corvus Pharmaceuticals, Inc.
+1-650-900-4522
llea@corvuspharma.com
MEDIA CONTACT:
Sheryl Seapy
Real Chemistry
+1-949-903-4750
sseapy@realchemistry.com
FAQ
What is the mechanism of action of Corvus Pharmaceuticals' (CRVS) soquelitinib?
What clinical trials is Corvus Pharmaceuticals (CRVS) currently conducting for soquelitinib?
Where was Corvus Pharmaceuticals' (CRVS) soquelitinib research published?
